PinPointe FootLaser announced it has received approval from the Therapeutic Goods Administration (TGA) for its new laser treatment for toenail fungus (Onychomycosis), certifying it has met the TGA’s consumer and health safety standards and can be offered by certified health care providers throughout Australia and New Zealand. The treatment, introduced in 2008, has been awarded the CE Mark certifying it has met European Union consumer health and safety standards, has been cleared for use in the treatment of toenail fungus in the EU, and can be offered by healthcare providers throughout Europe. Additionally, it is FDA cleared for applications in dermatology, plastic surgery, and podiatry in the United States.
John Strisower, CEO of PathoLase, noted: “Approximately 900 million people around the world suffer from toenail fungus, including millions in Australia and New Zealand. We’re very much looking forward to making PinPointe FootLaser available to practitioners in both countries, offering them an excellent opportunity for providing a unique and valuable service to their patients.”
No Comment Received
Leave A Reply